Chemcon Q1 FY27: Better realizations lift margins despite uneven volumes

Chemcon Speciality Chemicals Limited opened FY27 with a sharper profit profile even as topline and volumes stayed mixed. In Q1 FY27, revenue from operations came in at Rs 66.5 crore, up 24 percent year on year from Rs 53.5 crore. The bigger story was profitability. EBITDA nearly doubled to Rs 15.4 crore from Rs 7.7 crore, taking the EBITDA margin to 23.2 percent versus 14.5 percent a year ago. Profit after tax rose to Rs 11.0 crore, up 72 percent year on year, with PAT margin improving to 16.5 percent from 11.9 percent.

Management attributed the quarter to improved realizations across key products and steady demand in several categories. The Chairman and Managing Director, Mr. Kamal Aggarwal, described the quarter as a strong start to FY27, led by better pricing across the portfolio. The commentary also acknowledged that pricing pressure from global competition, particularly imports from China, continues in select products. Still, the operating environment was described as more favorable than the prior year, allowing profitability to recover meaningfully.

Chemcon operates across two main verticals. Organic chemicals include HMDS, CMIC, Bromobenzene and 2 Bromo. Inorganic chemicals refers primarily to bromides used in oilwell completion fluids. The quarter showed the benefits of a diversified portfolio, but also highlighted how quickly the revenue mix can shift between export and domestic markets.

A quarter of recovery: what changed under the hood

The income statement shows how the quarter was built. Revenue was higher year on year, but the step up in earnings was larger than the step up in sales. EBITDA rose 98 percent year on year. PAT increased 72 percent. Margins expanded across the chain, pointing to improved product realizations and a better cost structure relative to Q1 FY26.

Quarter on quarter, revenue fell 12 percent from Rs 75.4 crore in Q4 FY26 to Rs 66.5 crore in Q1 FY27. But EBITDA rose 74 percent and PAT rose 72 percent compared with Q4 FY26. This contrast matters because it suggests that the company is not relying only on volume growth to protect returns. It is also capturing better pricing or better mix, and keeping operating costs contained.

Other income remained steady at Rs 3.7 crore versus Rs 3.7 crore in Q1 FY26 and below Rs 4.2 crore in Q4 FY26. Depreciation rose to Rs 3.7 crore from Rs 2.7 crore a year ago, consistent with capacity additions over recent years. Finance cost stayed low at Rs 0.8 crore.

In the background, Chemcon’s FY26 base was Rs 240.0 crore of revenue, Rs 30.2 crore of EBITDA, and Rs 23.6 crore of PAT. Q1 FY27, therefore, begins the year with profitability running ahead of FY26 averages, even though quarterly revenue is below the Q4 FY26 run rate.

Mix matters: organic chemicals lead, exports normalize

Chemcon’s Q1 FY27 revenue mix remained led by organic chemicals, but export contribution eased sharply from the previous quarter. In Q1 FY27, exports were 31 percent of revenue, down from 47 percent in Q4 FY26. Domestic revenue rose to 69 percent from 53 percent in the prior quarter.

This export normalization is also visible in volumes. Total sales volume in Q1 FY27 was 2,066 MT versus 3,497 MT in Q4 FY26. The company notes that export data includes deemed exports, and the Q1 shift suggests either timing of shipments or a deliberate focus on domestic demand for the quarter.

Business wise, organic chemicals contributed 75 percent of revenue in Q1 FY27, compared with 71 percent in Q4 FY26 and 79 percent in Q1 FY26. Inorganic chemicals contribution was 13 percent, down from 24 percent in Q4 FY26 and 15 percent in Q1 FY26. The others category rose to 12 percent from 5 percent in Q4 FY26 and 6 percent in Q1 FY26.

Volume data reinforces the mix shift. Organic chemicals volumes were 1,236 MT in Q1 FY27 versus 1,525 MT in Q4 FY26. Inorganic chemicals volumes were 830 MT versus 1,972 MT in Q4 FY26. Despite lower volumes, profitability improved, which aligns with management’s focus on better realizations across key organic products such as HMDS, CMIC, Bromobenzene and 2 Bromo.

The segment commentary provides useful context. Organic chemicals delivered a notable improvement driven by realizations in HMDS, CMIC, Bromobenzene and 2 Bromo. The company also flagged continued pricing pressure in select products due to global competition and imports from China. Even so, the overall environment was described as more favorable than the previous year.

In inorganic chemicals, performance was described as stable with improved market conditions and improved demand year on year. Management also flagged uncertainty from geopolitical developments and crude oil volatility, which can influence oil drilling activity and chemical demand patterns. The segment’s recovery over the corresponding period last year indicates that the oilwell bromides portfolio remains relevant, but its quarter to quarter contribution can swing with demand and shipment timing.

Building a specialty chemicals platform: capacity, portfolio, and positioning

Chemcon’s longer term narrative is anchored in specialty manufacturing positions in select products and a steady expansion of its portfolio. The company was incorporated in 1988 and has built two manufacturing facilities in Vadodara, Gujarat, at Manjusar and Gothada. It operates 10 units and maintains six owned warehouses. It is ISO 9001:2015 and ISO 14001:2015 certified, and states it is a zero discharge company complying with environmental laws.

Several competitive positioning points stand out. Chemcon states it is the only manufacturer of HMDS in India, the third largest manufacturer of HMDS worldwide, and the largest manufacturer of CMIC worldwide. On the inorganic side, it is the only manufacturer of Zinc Bromide in India and the largest manufacturer of Calcium Bromide in India. These claims, combined with a two decade export track record and REACH compliance, support the idea that Chemcon is not competing only on price. It is building around manufacturing capability, customer qualification, and product criticality.

Capacity and product additions over time show a clear move up the value chain. HMDS began in 2001 and exports started in 2005. CMIC sales started in FY14-16, with multiple capacity expansions, including increases from 600 to 1,200 MTPA in FY18 and then to 1,800 MTPA in FY19. Oilwell completion chemicals capacity expanded from 7,200 to 14,400 MTPA in FY18. Recent years added CMIC and TMCS capacity via plant P8 and expanded bromobenzene capacity via plant P-9. In FY25, the company added 2 Bromo with a capacity of 600 MTPA. In FY26, Chemcon acquired Shivam Petrochem Industries through a slump sale.

The current manufacturing table in the presentation lists installed capacity of 11,400 MTPA for organic chemicals including HMDS, CMIC, Bromobenzene, 2 Bromo and ancillary products, and 15,000 MTPA for inorganic bromides. It also notes an upcoming facility at the P-11 unit for organic chemicals.

Strategically, the company’s stated growth drivers are straightforward. It plans capacity expansion at the P11 unit for organic chemicals. It wants to pursue import substitution opportunities in organic chemicals in India. It is exploring new applications to diversify the portfolio and client base. And it is targeting cost efficiencies through process re engineering, optimized raw material consumption, and scale benefits.

These themes connect back to Q1 FY27 performance. Better realizations drove profit expansion, but management also acknowledged price pressure from imports in select products. In that context, import substitution is not only a growth opportunity. It is also a defensive posture, strengthening domestic supply reliability and customer engagement while managing competition.

What the longer term numbers say about resilience

Chemcon’s multi year financial trends show the business has navigated a volatile period. Total revenue was Rs 257.1 crore in FY22 and rose to Rs 302.9 crore in FY23, then moderated to Rs 267.1 crore in FY24 and Rs 207.4 crore in FY25, before recovering to Rs 240.0 crore in FY26.

Profitability has also cycled. EBITDA was Rs 81.6 crore in FY22 and Rs 70.7 crore in FY23, then dropped to Rs 26.9 crore in FY24. It recovered modestly to Rs 32.9 crore in FY25 and Rs 30.2 crore in FY26. PAT followed a similar path, from Rs 62.8 crore in FY22 and Rs 55.1 crore in FY23 to Rs 19.2 crore in FY24, then Rs 24.5 crore in FY25 and Rs 23.6 crore in FY26.

Mix shifts are part of this story. Export contribution was 37 percent in FY22, jumped to 59 percent in FY23, then settled at 41 percent in FY24, 37 percent in FY25, and 41 percent in FY26. The business wise revenue share has also moved. Inorganic chemicals peaked at 39 percent in FY24, while organic chemicals returned to 74 percent in FY26.

Volumes have also varied. Total volume was 10,076 MT in FY22, 10,975 MT in FY23, and 12,131 MT in FY24, before falling to 10,213 MT in FY25 and 9,991 MT in FY26. Importantly, FY26 volumes show a different composition versus earlier years: organic volumes rose to 5,560 MT while inorganic volumes fell to 4,431 MT. That aligns with the company’s emphasis on organic chemicals and newer products like bromobenzene and 2 Bromo.

In this context, Q1 FY27’s margin expansion looks like a continuation of FY26’s rebuilding phase rather than a one off. The quarter indicates that the company can generate stronger profitability even when volumes and exports are not at peak levels.

Closing takeaways: realization led execution with a clear playbook

Chemcon’s Q1 FY27 can be read as a quarter where execution quality showed up in margins. Revenue growth of 24 percent year on year was healthy, but the doubling of EBITDA and the sharp rise in PAT signaled that improved realizations and mix mattered more than pure volume. Organic chemicals remained the anchor at 75 percent of revenue, supported by improved pricing in HMDS, CMIC, Bromobenzene and 2 Bromo.

The quarter also highlighted a few investor relevant realities. Export share can move quickly quarter to quarter, and inorganic bromides can be influenced by oil market uncertainty and geopolitics. But Chemcon’s strategy is consistent. It is expanding capacity through the upcoming P11 unit, focusing on import substitution in organic chemicals, broadening applications, and pursuing cost efficiencies.

The near term theme is disciplined recovery. If realizations remain supportive and the company continues to build its newer portfolio while protecting its specialty positions, the quarter sets a base for more stable and profitable growth through the rest of FY27.